AlloVir Inc. said Thursday that its upsized initial public offering priced at $17 a share, in the middle of the expected range of $16 to $18 a share. The company sold 16.25 million shares to raise $276.25 million, up from previous expectations to sell 14.75 million shares. With 61.17 million shares outstanding after the IPO, the IPO pricing values the cell therapy company at about $1.04 billion. The lead underwriters of the IPO are Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler. The stock is expected to begin trading on the Nasdaq exchange under the ticker symbol "ALVR."